## Index

Note: page numbers in *italics* refer to figures, those in *bold* refer to tables and boxes. Page numbers with suffix ‘n’ refer to footnotes.

<table>
<thead>
<tr>
<th>Term</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abnormal Involuntary Movement Scale</td>
<td>176–8</td>
</tr>
<tr>
<td>accountability</td>
<td>92</td>
</tr>
<tr>
<td>activity–passivity</td>
<td>139</td>
</tr>
<tr>
<td>adherence to treatment</td>
<td>8–10, 114–30</td>
</tr>
<tr>
<td>ambivalence</td>
<td>166</td>
</tr>
<tr>
<td>antipsychotics</td>
<td>24</td>
</tr>
<tr>
<td>assessment</td>
<td>121, 122, 123–8</td>
</tr>
<tr>
<td>clinical practice</td>
<td>116–18</td>
</tr>
<tr>
<td>collection of medication</td>
<td>126–7</td>
</tr>
<tr>
<td>consequences</td>
<td>193</td>
</tr>
<tr>
<td>extent</td>
<td>115–16</td>
</tr>
<tr>
<td>factors affecting</td>
<td>116</td>
</tr>
<tr>
<td>improvement</td>
<td>11–12</td>
</tr>
<tr>
<td>information giving</td>
<td>128–9</td>
</tr>
<tr>
<td>intervention</td>
<td>121, 122, 123–8</td>
</tr>
<tr>
<td>polypharmacy</td>
<td>6</td>
</tr>
<tr>
<td>psychiatrists concerns about</td>
<td></td>
</tr>
<tr>
<td>consequences of adverse effects</td>
<td></td>
</tr>
<tr>
<td>explanation</td>
<td>141–2</td>
</tr>
<tr>
<td>remembering to take medication</td>
<td>125–6</td>
</tr>
<tr>
<td>side-effects</td>
<td>124</td>
</tr>
<tr>
<td>support</td>
<td>127–8</td>
</tr>
<tr>
<td>see also Brief Evaluation of Medication</td>
<td></td>
</tr>
<tr>
<td>Influences and Beliefs (BEMIB);</td>
<td></td>
</tr>
<tr>
<td>concordance; non-adherence</td>
<td></td>
</tr>
<tr>
<td>advanced directives</td>
<td>162, 195</td>
</tr>
</tbody>
</table>

| advanced refusal                        | 93      |
| adverse effects                         |         |
| incidence                               | 95      |
| information delivery                    | 139–41  |
| minimising                              | 3       |
| practitioner advocacy role              | 4       |
| psychiatrists concerns about            |         |
| consequences of explanation             | 141–2   |
| see also side-effects                   |         |
| advocacy, practitioner role             | 4, 6, 163–4 |
| affect, inappropriate                   | 104     |
| aggression management                   | 226–9   |
| PRN psychotropic medication             | 228     |
| rapid tranquillisation                  | 228–9   |
| agranulocytosis                         | 51      |
| akathisia                               | 210     |
| typical antipsychotics                  | 26      |
| alcohol                                 |         |
| consumption                             | 72      |
| drug interactions                       | 65–8, 73, 77 |
| alliance therapy                        | 11–12   |
| alpha-1 adrenergic antagonism           | 25, 27  |
| Alzheimer’s disease                     | 46      |
| cholinesterase inhibitors               | 7, 46   |
| consent to treatment                    | 7, 8    |
| γ-aminobutyric acid (GABA)              | 35      |
| amitriptyline                           | 36      |
| drug interactions                       | 61      |

---

amphetamines, psychotropic medication interactions 65–8
anti-anxiety medicines 41–2
anti-convulsants 34–5
blood disorders 52
antidepressants 36–41
anti-anxiety 41, 42
atypical 36, 37
blood-related side effects 51
discontinuation syndrome 39–40
dosage 37
drug interactions 38–9
effectiveness 36–7
mechanisms of action 36–7
serotonin syndrome 39
sexual dysfunction 38, 39
side-effects 38–9
antihistamines 45
Antipsychotic Non-Neurological Side Effect Rating Scale (ANNSERS) 177, 178
antipsychotics 23–32
adherence to treatment 24
atypical 24, 28–30
co-prescribing 30
drug interactions 30
effectiveness 29–30
mechanism of action 28–9
blood disorders 51
mood stabilisers 35
prolonged QTc interval 50
prolonged use 103–4
side-effect self-management 24
third generation 30–2
co-prescribing 31–2
drug interactions 31–2
effectiveness 31
mechanism of action 31
typical 24–8
co-prescribing 28
drug interactions 28
effectiveness 25
mechanism of action 24–5
PRN 230
side-effects 25
anxiety
anti-anxiety medicines 41–2
reduction 161
treatment in primary care 6–7
anxiolytics 41–2
aripiprazole 24, 31–2
assessment
informal 170–2
measures 172–3
symptom measures 173–5
therapeutic alliance 173
assistant technical officers 148
Attitudes towards Neuroleptic Treatment (ANT) 182
auditory hallucinations, assessment 174
autonomy 10
decision-making 162
information sharing 161
barbiturates 44
Barnes Akathisia Rating Scale 177, 178
beliefs, medicines 166, 192, 193, 194–5, 209
beneficence 91
benzodiazepines
addiction 43–4
anti-anxiety 41, 42–4
drug interactions 43, 77
inpatient use 227, 229
mechanism of action 42–3
side-effects 43, 229
tolerance 43–4
withdrawal symptoms 44
best interests, service users 92–3, 117
beta-blockers, anti-anxiety 45
biography construction 193
bio-psychosocial stressors 157
bipolar disorder
case study 76–8
mood stabilisers 32–4
black people, service users 13–14
blood dyscrasias 51–2
Bolam principle 91
Bolitho case 91
brainstorming 217
Brief Evaluation of Medication Influences and Beliefs (BEMIB) 121, 122, 123–8, 182
buprenorphine 72
buspirone 44
butyrophenones 24
caffeine intake 171–2
Calgary Depression Scale 174–5
cannabis
drug interactions 72, 77
psychotropic medication interactions 65–8
capacity 92, 93, 94
consent 162
carbamazepine 35, 36
blood disorders 52
drug interactions 77
substance interactions 67
cardiac arrhythmias 50, 180
cardiac repolarisation delay, typical antipsychotics 28
cardiovascular risk 180
care coordinators 4
care plans 162
carers
engagement 159
information about medicines 192
information provision 127–8
central nervous system (CNS)
depression 72
change management 234–6
chlorpromazine 23–4
blood disorders 51
side-effects 27
substance interactions 65
cholinesterase inhibitors
Alzheimer’s disease 7, 46
drug interactions 47
effectiveness 47
mechanisms of action 46
side effects 47
civil proceedings 92
clinical management plan (CMP), supplementary prescribing 85–6
clinical pharmacy 150–1, 154
clinicians, traditional 103–6
clozapine 24
blood disorders 51
haematological adverse effects 51
side-effects 29, 30
smoking interactions 74
substance interactions 65
cocaine, psychotropic medication interactions 65–8
cognitive behavioral therapy (CBT) 36
problem solving 211, 212
cognitive model for change management 236
collaboration, medication management 199, 204
collaborative crisis care plans 162
collaborative relationship 4–8, 11, 156–67
case study 164–6
engagement 159–60
medicines management 196
common law 92
communication
adverse effects 139–41
blocking 137
information 118
interpersonal conflicts 118
language use 163
questioning 201
self-awareness 160–1
speech delivery 140
community, mental health care/treatment 151
community mental health nurses (CMHN), training 12
community mental health practitioners (CMHP), training 12
community pharmacies 147
service user relationships 159
co-morbid conditions 75
compensationalist culture 92
competency, non-medical prescribing 89–90
compliance 114–15
compliance therapy 11, 128
concordance 10, 107–8, 114–15
achieving 189–206
emotional issues 115
ethical issues 115
legal issues 115
see also adherence to treatment
confidence, non-medical prescribing 90
conflict resolution 118
consent to treatment 8–10, 92–4
Alzheimer’s disease 7, 8
capacity 162
medication management 200, 205–6
see also informed consent
consultation process, concordance 107
consultations, shared 119
coping mechanisms 128
counselling, practitioner role 164
cultural issues 13–14
  expectations 191
  self-awareness 160–1
cytochrome P450 enzymes 49
  actions 62–3
  carbamazepine induction 35
  drug interactions 62–3
  smoking 63, 74
decision-making
  autonomy 162
  exercises 192–5
  health care negotiator skill development 191
  medicines 108–9, 117, 134
  beliefs 193
  negotiated 137–9
  prescribing 133–43
  by psychiatrist 135–6
  service users 135
  shared 118–21, 134–6, 138–9
  side-effect impact 193
delusions
  assessment 174
  bizarre 104
dementia
  medicines 45–6, 47
  see also Alzheimer’s disease
denial 128
depression
  clinical management plan 86
  problem solving 212, 213
  psychosocial interventions 36
  symptom assessment 174–5
  see also antidepressants
Diagnostic and Statistical Manual of Mental Disorders 104
distress, root cause 105
diversity, respect for 13–14
doctor–patient relationship 138–9
donepezil 46
  NICE guidance 48
dopamine antagonists 25
dopamine D2 receptors, antagonists 25–6, 28–9
dosing regime, development 5–7
Drug Attitude Inventory (DAI) 182
drug interactions 58–78
  alcohol 65–8, 73
  case study 76–8
categories 61–2
  effect increase 60
  effectiveness impact 59
  extent of problem 64, 69
  nicotine 73–4
  pharmacodynamic 61
  pharmacokinetic 62
  potential 60
  risk assessment 60
  side effects 59
  smoking 63–4, 73–4
  substance (mis)use 64, 65–8, 69–74
  types 60–1
drug/condition interactions 61
drug/drug interactions 60–1
drug/food/drink interactions 61
dual diagnosis 64, 70–1
  case study 76–8
duty of care 91
dystonic reactions, typical antipsychotics 26
estasy, psychotropic medication
  interactions 65–8
emergency psychiatry 226–9
emotional issues
  concordance 115
  practitioners in non-adherence 117
  emotional state of organisation 236
  empathy 158
  empowerment 7–8
  service users 12–13, 14, 107–8
  engagement 3, 156–67
  carers 159
  case study 164–6
  core skills for development 157–8
  informed choice 161–2
  necessity 157
  self-assessment 159–60
  self-awareness 160–1
ethical issues
  concordance 115
  non-medical prescribing 86, 91
ethical practice 14
  evidence base 10–13
  prescribing 97
  problem solving 213
  evidence-based care 115
excitotoxicity 46
exploration of problems 120
extrapyramidal side effects (EPSEs) 210
assessment scales 176–8
atypical antipsychotics 29, 30
lithium 33–4
typical antipsychotics 27

family members
involvement 159
support 127–8
flexibility 158
fluoxetine 37

substance interactions 68
flupentixol, substance interactions 65
fluphenazine, blood disorders 51
friends
involvement 159
support 127–8

galantamine 46
drug interactions 47
NICE guidance 48
general practice, practice pharmacists 147
general practitioners, medicines reviews 209
generalised anxiety disorder (GAD) 42
genuineness 158
Glasgow Antipsychotic Side Effect Scale 177, 178–9
‘go between’ role 162–3
goals
achievement 217, 219
setting 193–4
good prescribing practice 97
guidance–cooperation approach 138, 139
guided discovery 120
medication management 200–1, 205

H1 histamine antagonism, typical antipsychotics 25, 27
hallucinations, assessment 174
hallucinogens 73
haloperidol
acute psychosis 227
blood disorders 51
promethazine combination 227
substance interactions 65
Harold Shipman case 86
Health and Social Care Act (2001) 84
health care, negotiator skill development 191–2
health promotion advice, access to 180–1
health screen, annual 181
high-dose prescribing 5–6
definition 224n
inpatients 224–6
prevalence 225
PRN psychotropic medication 230
Hospital Depression and Anxiety Scale (HADS) 175
Hypericum perforatum (St John’s wort) 40–1
hypnotics, non-benzodiazepine 44–5
iatrogenesis 95
independent prescribing 86–7, 95
inequality, challenging 14
information
adverse effects 139–41
formal assessment 172
giving 128–9, 192
medication choice 224
medicines information services 151
needs 209, 210–11
provision
carers 127–8
inpatient administration of medication 233
sharing 161
side-effects 139–41
informed choice 161–2, 224
informed consent 162–4
information giving 128–9
inpatient settings 223–36
benzodiazepines use 227, 229
high doses 224–6
medication administration 231–3, 234–6
polypharmacy 224–6
psychotropic medication administration 231–3, 234–6
service users’ perceptions of medication 223–4
therapeutic engagement 233
see also pro re nata (PRN) psychotropic medication
insight 128
integrative style 128
interactional styles 139
interpersonal conflicts, communication 118
key-workers 4
kidney disease 75
knowledge, needs 209, 210–11
Kraweika, Goldberg and Vaughn (KGV) Scale 173–4, 175, 183
lamotrigine 35, 36
language use 163
lasting power of attorney (LPA) 93
reviews 96, 209
service users
  experiences 105
  understanding development 190–2
short-term use 111
strategies for taking 125
structured assessment for administration 234–5
supplying 88–9
taking 209, 210
treatment protocols 235
using 106–8
see also personal medicine; pro re nata (PRN) psychotropic medication;
psychotropic medications;
side-effects
memantine 46
drug interactions 47
mechanisms of action 46–7
side effects 47
memory, short-term 46, 210
Mental Capacity Act (2005) 92–3
mental clouding, underestimation 136–7
Mental Health Act (1983) 93
Mental Health Amendments Act (2007) 93
mental health trust, pharmacy services 149–50
mental illness, self-fulfilling prophecies 103–4
meso-cortical blockade, typical antipsychotics 26
metabolic syndrome 180
methadone 72, 77
mini-mental state examination (MMSE) 48
Misuse of Drugs Act (2001) 94
moclobemide 37
monitoring
effectiveness of medication administration 233
service users 121
weight gain 179
monoamine oxidase inhibitors (MAOIs) 36–7
discontinuation syndrome 40
side-effects 38
monotherapy 96
mood stabilisers 32–5
anti-convulsants 34–5
antipsychotics 35
bipolar disorder 32–4
lithium 32–4
multidisciplinary team 154
mutual participation 139
naloxone 72
naltrexone 72
National Institute for Clinical Excellence (NICE) guidelines 169–70
Alzheimer’s disease drugs 46, 48
antidepressants 36
anxiolytics 41
drug interactions 75
monotherapy 96
rapid tranquillisation 228
St John’s wort 41
National Patient Safety Agency (NPSA) 95
patient safety incidents 228
National Prescribing Centre 90
National Service Framework (NSF) for mental health 151
National Treatment Agency (NTA), drug interactions guidance 75
negligence 91
neuroleptic malignant syndrome (NMS) 27–8
new ways of working (NWW) 16–17, 148, 153
nicotine
drug interactions 73–4
psychotropic medication interactions 65–8
nicotine replacement therapy (NRT) 63–4
nigro-striatal blockade, typical antipsychotics 26
non-adherence 8–10, 209
causes 116
consequences 193
extent 115–16
non-compliance 107
non-maleficence 91
non-medical prescribing 17, 83–98
  competency 89–90
  confidence 90
  enabling Acts 84
  ethical issues 86, 91–2
  future developments 87–8
  independent prescribing 86–7, 95
  legal issues 86, 91–2
  medicines management policy 94–5
Index

non-mental health drugs 97
nurse prescribing 17
extended formulary 85
independent 86–7
limited formulary 84–5
peer support 90
practice 88–9
practice pharmacists 147
service level agreements 89
supplementary prescribing 85–6, 87, 95
see also consent to treatment
nurse prescribing 17
extended formulary 85
independent 86–7, 95
limited formulary 84–5
non-mental health drugs 97
supplementary prescribing 85–6, 95
see also supplementary prescribing

obsessive compulsive disorder (OCD) 42
oculogyric crisis, typical antipsychotics 26
olanzapine 24
blood disorders 51
drug interactions 77
side-effects 30
one-stop dispensing 152–3
opiates
drug interactions 72
psychotropic medication interactions 65–8
tricyclic antidepressant interactions 71–2
panic disorder 42
paroxetine 37
partnership working 13
enabling service users 118–21
partnerships, building 119
paternalistic role 163–4
patient group directions (PGDs) 88, 95
patient-centred practice 135
patients’ own drugs (PODs) 152, 153
peer support 90, 111
group 112
pericyazine, side-effects 27
personal development 16
personal medicine 106–7, 108
personal responsibility 106
person-centred approach 158
Pharmaceutical Services Regulations (1994) 84

pharmacists
clinical 150–1, 154
community 147, 159
mental health trusts 150
multidisciplinary team 154
primary care trust 147
secondary care 147–9
service user relationships 159
pharmacy, clinical 150–1
pharmacy assistants 148
multidisciplinary team 154
pharmacy services 145–55
clerical staff 148–9
community 147
medicines information services 151
medicines
management
schemes/interventions 151–4
mental health trust 149–50
multidisciplinary team 154
new ways of working 148, 153
organisation 147–9
primary care trust pharmacists 147
secondary care pharmacists 147–9
specialist mental health clinical pharmacists 150–1
support staff 148–9
pharmacy technicians 148
mental health trusts 150
multidisciplinary team 154
phenelzine 36
phenothiazines 24
prolonged QTc interval 50
physical exercise 179–80
physical health 171
evaluation 179–81
needs assessment 181
quality of care 180
screening 180–1
specialist services 181
polycyclic hydrocarbons 63
polypharmacy 5–6
cardiac arrhythmia risk 180
definition 224n
inpatient settings 224–6
prevalence 225
PRN psychotropic medication 230
side-effects 96
poly-substance abuse, case study 76–8
positive regard, unconditional 158

252 Index
Index 253

post-traumatic stress disorder (PTSD) 42
practice pharmacists 147
practice rituals 161–2
practitioner roles 4–5
  advocacy 4, 6, 163–4
  counselling 164
  empowerment 7–8
  leadership 164
practitioners
  emotional support provision 15–16
  learning 16
  personal development 16
  teaching medication management 12–13
pragmatism 158
prescribing
  decision negotiation 133–43
  decision-making 133–43
  evidence base 97
  mental health 95–7
  negotiated decision 137–9
  new ways of working 16–17, 148, 153
  non-medical 17
  psychiatrist decision-making 135–6
  rationale 161–2
  record keeping 96–7
  service users
    decision-making 135
    relationship 96
  see also non-medical prescribing; nurse prescribing
Prescribing Observatory for Mental Health UK (POMH-UK) 226n
prescriptions 3
  history 193
primary care
  anxiety treatment 6–7
  problem solving 212, 213
primary care trust pharmacists 147
Prince Henry Hospital Akathisia Rating Scale 177, 178
pro re nata (PRN) psychotropic medication 223, 225, 226, 230–1
  aggression control 228
  benzodiazepines 229
problem solving 208–20
  advantages of options 217, 219
  case study 218, 219–20
  definition 211
  development 211–12
  disadvantages of options 217, 219
effectiveness 213
  evidence base 213
  five-step approach 212, 214–18, 219–20
  funnel technique 215
  goal achievement 217, 219–20
  goal setting 216, 219
  history 211–12
  option choice 217–18, 219
  problem definition 212, 214–16, 219
  problem statements 215–16
  process 214
  review 218, 219
  severity rating of problem 216
  steps 212, 214–18, 219–20
  techniques 36
  worst case scenario identification 218, 219
problem solving therapy 213
  product licences 97
professionals 109–10
  responsibilities 111
professional practitioners
  emotional concern in non-adherence 117
  problems associated with medicines 209
  professional relationships 117–18
  professional thought disorder (PTD) 104
  professional–client relationship 139
  prolonged QTc interval 50
  atypical antipsychotics 30
  typical antipsychotics 28
promethazine 45
  haloperidol combination 227
  propranolol, anti-anxiety 45
pseudo-parkinsonism, typical antipsychotics 26
Psychiatric Assessment Scale (PAS) see
  Kraweika, Goldberg and Vaughn (KGV) Scale
psychiatrists
  communication blocking 137
  consequences of explanation of adverse effects 141–2
  decision-making 135–6
  engaging with service users’ concerns 136–7
  medicines reviews 209
psychodynamic theory of nursing 163n
psychological reactance 10
psychosis, acute 227
psycho-social interventions (PSI) 212, 213
Psychotic Symptom Rating Scale 174
psychotropic medications 23–52
administration 231–3, 234–6
effectiveness monitoring 233
managing change 234–6
procedure 232
blood dyscrasias 51–2
drug interactions 49
information provision 233
non-prescribed drug interactions 71–4
risks 49–52
substance interactions 65–8, 71–4
therapeutic engagement 233
see also pro re nata (PRN) psychotropic medication
questioning 201
quetiapine 24

race issues 13–14
rash, anti-convulsants 34–5
Rating of Medication Influences (ROMI) scale 182
recall bias 139
record keeping 96–7
recovery 108–12
concept 8
medicines decision-making 117
medicines requirement 105
promotion 14
style 128
support for service user 106
reflection 118, 165
rehabilitation, medicines requirement 105
reliability, assessment tools 172
resistance, avoidance 161
respiratory depression 72
response to treatment, self-assessment 183–4
restraint
aggression control 228
chemical/physical 227–8
reversible monoamine oxidase inhibitor (RIMA) 37
reviews of medication 96, 209
risk taking, positive 15–16
risk–benefit analysis 95–6
risperidone 24

blood disorders 51
side-effects 29
substance interactions 65
rivastigmine 46
NICE guidance 48

safety promotion 15–16
St John’s wort 40–1
Satisfaction with Information about Medicines Scale (SIMS) 183
Scale for the Assessment of Thought, Language and Communication 175
Schedule One drugs 85
schizophrenia 8–9
‘sealing over’ recovery style 128
seclusion, aggression control 228
secondary care, problem solving 213
sedation
benzodiazepines 229
underestimation of side-effect 136–7
selective serotonin reuptake inhibitors (SSRIs) 36, 37
anti-anxiety 41, 42
blood disorders 51
discontinuation syndrome 40
drug interactions 38
side-effects 38–9
substance interactions 68
self-assessment
engagement 159–60
response to treatment 183–4
side-effects 183–4
symptoms 183–4
self-awareness 160–1
self-care packages 11
self-care strategies 106, 107
self-efficacy 8, 10, 12–13
self-assessment benefit 184
self-help techniques 36
self-management of medication 3, 8, 10–12
self-rating 184
sense of self 105
serotonin 5-HT2A antagonists 29
serotonin noradrenaline re-uptake inhibitor (SNRI) 37
serotonin syndrome 39
St John’s wort 41
sertindole, prolonged QTc interval 50
service level agreements 89
pharmacy services 149
service users
ability to take medications 200, 205
assertiveness 111
assessment 165, 170
informal 170–2
best interests 92–3, 117
bio-psychosocial stressors 157
black people 13–14
care provision 15
collaborative working 156–67
decision-making 135
empowerment 12–13, 14, 107–8
enabling 118–21
engagement 3, 156–67
engaging with concerns 136–7
experience of medications 105
evaluation 200, 205
exploration of problems 120
illness management programmes 12–13
information about medicines 192
inpatient settings 223–4
involvement in drug decisions 133–4
medication
beliefs 166
issues 189–206
management 3, 8, 10–12
understanding development 190–2
using 106–8
monitoring 121
personal responsibility 106
perspective 102–12
pharmacist relationships 159
physical care 97
preference conflict with evidence-based care 115
problem solving 211
relationship with prescriber 96
responsibilities 111
self-assessment 183–4
self-efficacy 8, 10, 12–13
self-management of medication
skills 15
teaching 10–12
self-rating 184
strategy sharing 111
support 106
timescales 196–7
side-effects
adherence to treatment 124
antipsychotic prolonged use 103–4
assessment measures 176–9
benzodiazepines 43, 229
decision-making impact 193
information delivery 139–41
mental clouding underestimation 136–7
polypharmacy 5–6, 96
problems 209, 210
sedation underestimation 136–7
self-assessment 183–4
self-management 24
service user concerns 166
typical antipsychotics 25–8
underestimation 136
see also adverse effects
Simpson and Angus Scale (SAS) 176–8
SMART formula 202, 206
goal setting 216
smoking
clozapine interactions 74
cytochrome P450 enzymes 63, 74
drug interactions 63–4, 73–4
psychotropic medication
interactions 65–8
quitting 63–4, 70
substance misuse 70
social phobia 42
social withdrawal 136
Socratic dialogue 201
speech delivery 140
Spread Programme 153–4
Stevens–Johnson syndrome 34–5
stimulant abuse 72–3
stressors, bio-psychosocial 157
substance (mis)use 64, 65–8, 69–74
supervision 235
role 16
supplementary prescribing 85–6, 87, 95
support groups, user-led medication
reduction 112
surrogate role 163–4
Survivors Speak Out 104
symptoms, self-assessment 183–4
tardive dyskinesia
information provision 192
screening 177
typical antipsychotics 26
therapeutic alliance 3, 117
assessment 173
therapeutic engagement, inpatient settings
   233
therapeutic relationship 4
thioridazine, prolonged QTc interval 50
thioxanthenes 24
timelines 192–3
torsades de pointes 50
training
   community mental health nurses/practitioners 12
   treatment evaluation assessment 175
   translation dimension of mental health
   nursing 162–3
transquilisation, rapid 228–9
treatment evaluation 169–85
   assessment 170
      informal 170–2
      measures 172–3
      side-effects 176–9
      training 175
   attitudes to treatment 182–3
      key measures 173–9
   physical health evaluation 179–81
   self-assessment of response to
      treatment 183–4
      side-effects measures 176–9
   treatment protocols 235
   triazolam, substance interactions 66
   tricyclic antidepressants 36
   agranulocytosis 51
   discontinuation syndrome 40
   opiate interactions 71–2
   prolonged QTc interval 50
   side-effects 38
   trifluoperazine, side-effects 27
   tuberoinfundibular pathway dopamine
      blockade 27
   Udvalg for Kliniske Undersogelser (UKU)
      scale 176, 177
   user-led medication reduction support
      groups 112
   user-led services 111
   validity, assessment tools 172
   valproate 35, 36
   venlafaxine 36, 37
   vicarious liability 94
   violence 227–8
   weight gain 180
      atypical antipsychotics 29–30
      monitoring 179
   workforce skills 13–17
   worst case scenario identification 218, 219
   Young’s Mania Rating Scale 175
   zolpidem 44–5
   zopiclone 44–5